Shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) dropped 1.8% on Monday . The company traded as low as $5.91 and last traded at $5.93, with a volume of 1,534,740 shares. The stock had previously closed at $6.04.

ZIOP has been the subject of a number of analyst reports. Wells Fargo & Co. reiterated a “sell” rating on shares of Ziopharm Oncology in a report on Thursday, May 19th. Vetr lowered shares of Ziopharm Oncology from a “strong-buy” rating to a “buy” rating and set a $9.76 target price for the company. in a report on Monday, April 18th. Zacks Investment Research lowered shares of Ziopharm Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, May 31st. Griffin Securities reiterated a “buy” rating and set a $21.00 target price on shares of Ziopharm Oncology in a report on Friday, July 1st. Finally, Mizuho increased their target price on shares of Ziopharm Oncology from $6.00 to $7.00 and gave the stock a “neutral” rating in a report on Wednesday, May 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $11.07.

The company’s market capitalization is $772.18 million. The company has a 50 day moving average of $6.45 and a 200 day moving average of $7.03.

Ziopharm Oncology (NASDAQ:ZIOP) last issued its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.01. The business had revenue of $1.97 million for the quarter, compared to analyst estimates of $1.89 million. During the same quarter last year, the firm earned ($0.69) EPS. The company’s quarterly revenue was up 623.9% compared to the same quarter last year. Equities research analysts anticipate that Ziopharm Oncology Inc. will post ($0.42) EPS for the current fiscal year.

A number of hedge funds and institutional investors recently modified their holdings of ZIOP. Morgan Stanley raised its position in shares of Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares during the last quarter. California Public Employees Retirement System raised its position in shares of Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock worth $2,554,000 after buying an additional 261,300 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock worth $1,766,000 after buying an additional 3,354 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Ziopharm Oncology by 18.4% in the fourth quarter. Wells Fargo & Company MN now owns 168,616 shares of the biotechnology company’s stock worth $1,402,000 after buying an additional 26,233 shares during the last quarter. Finally, Swiss National Bank raised its position in shares of Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares during the last quarter.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.